When choosing statin therapy: The case for generics

Jonas B. Green, Joseph S. Ross, Cynthia A. Jackevicius, Nilay D. Shah, Harlan M. Krumholz

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

The development of 'Top 5' lists across specialties and at regular intervals can help to remind physicians that optimal care is often possible at a lower cost. For purposes of cardiovascular risk reduction, generic statins, or their brand equivalents if priced similarly, remain the appropriate choice for dyslipidemic patients initiating statin therapy. In this article, we review the evidence supporting the choice of generic statins.

Original languageEnglish (US)
Pages (from-to)229-232
Number of pages4
JournalJAMA internal medicine
Volume173
Issue number3
DOIs
StatePublished - Jan 11 2013

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'When choosing statin therapy: The case for generics'. Together they form a unique fingerprint.

  • Cite this

    Green, J. B., Ross, J. S., Jackevicius, C. A., Shah, N. D., & Krumholz, H. M. (2013). When choosing statin therapy: The case for generics. JAMA internal medicine, 173(3), 229-232. https://doi.org/10.1001/jamainternmed.2013.1529